Does off-label dosing of NOACs increase the risk of adverse events in U.S. patients with atrial fibrillation?
U.S. patients in the community with atrial fibrillation (from the ORBIT-AF II registry)
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) dosed inconsistently with labeling (over- and underdosing)
NOAC doses consistent with labeling
Adverse eventssafety
Off-label dosing of NOACs is common in community practice (almost 1 in 8 patients) and is associated with an increased risk of adverse clinical events.
A significant minority (almost 1 in 8) of U.S. patients in the community received NOAC doses inconsistent with labeling. NOAC over- and underdosing are associated with increased risk for adverse events. (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II ORBIT-AF II; NCT01701817).
Building similarity graph...
Analyzing shared references across papers
Loading...
Benjamin A. Steinberg
Peter Shrader
Laine Thomas
Journal of the American College of Cardiology
Harvard University
Stanford University
Columbia University
Building similarity graph...
Analyzing shared references across papers
Loading...
Steinberg et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69d56dc675589c71d767d084 — DOI: https://doi.org/10.1016/j.jacc.2016.09.966